@article{fdi:010082273,
  title = {{P}rolonged {SARS}-{C}o{V}-2 {RNA} virus shedding and lymphopenia are hallmarks of {COVID}-19 in cancer patients with poor prognosis},
  author = {{G}oubet, {A}. {G}. and {D}ubuisson, {A}. and {G}eraud, {A}. and {D}anlos, {F}. {X}. and {T}errisse, {S}. and {S}ilva, {C}. {A}. {C}. and {D}rubay, {D}. and {T}ouri, {L}. and {P}icard, {M}. and {M}azzenga, {M}. and {S}ilvin, {A}. and {D}unsmore, {G}. and {H}addad, {Y}. and {P}izzato, {E}. and {L}y, {P}. and {F}lament, {C}. and {M}elenotte, {C}. and {S}olary, {E}. and {F}ontenay, {M}. and {G}arcia, {G}. and {B}alleyguier, {C}. and {L}assau, {N}. and {M}aeurer, {M}. and {G}rajeda-{I}glesias, {C}. and {N}irmalathasan, {N}. and {A}prahamian, {F}. and {D}urand, {S}. and {K}epp, {O}. and {F}errere, {G}. and {T}helemaque, {C}. and {L}ahmar, {I}. and {F}ahrner, {J}. {E}. and {M}eziani, {L}. and {A}hmed-{B}elkacem, {A}. and {S}aidani, {N}. and {L}a {S}cola, {B}. and {R}aoult, {D}. and {G}entile, {S}. and {C}ortaredona, {S}{\'e}bastien and {I}ppolito, {G}. and {L}elouvier, {B}. and {R}oulet, {A}. and {A}ndre, {F}. and {B}arlesi, {F}. and {S}oria, {J}. {C}. and {P}radon, {C}. and {G}allois, {E}. and {P}ommeret, {F}. and {C}olomba, {E}. and {G}inhoux, {F}. and {K}azandjian, {S}. and {E}lkrief, {A}. and {R}outy, {B}. and {M}iyara, {M}. and {G}orochov, {G}. and {D}eutsch, {E}. and {A}lbiges, {L}. and {S}toclin, {A}. and {G}achot, {B}. and {F}lorin, {A}. and {M}erad, {M}. and {S}cotte, {F}. and {A}ssaad, {S}. and {K}roemer, {G}. and {B}lay, {J}. {Y}. and {M}arabelle, {A}. and {G}riscelli, {F}. and {Z}itvogel, {L}. and {D}erosa, {L}.},
  editor = {},
  language = {{ENG}},
  abstract = {{P}atients with cancer are at higher risk of severe coronavirus infectious disease 2019 ({COVID}-19), but the mechanisms underlying virus-host interactions during cancer therapies remain elusive. {W}hen comparing nasopharyngeal swabs from cancer and noncancer patients for {RT}-q{PCR} cycle thresholds measuring acute respiratory syndrome coronavirus-2 ({SARS}-{C}o{V}-2) in 1063 patients (58% with cancer), we found that malignant disease favors the magnitude and duration of viral {RNA} shedding concomitant with prolonged serum elevations of type 1 {IFN} that anticorrelated with anti-{RBD} {I}g{G} antibodies. {C}ancer patients with a prolonged {SARS}-{C}o{V}-2 {RNA} detection exhibited the typical immunopathology of severe {COVID}-19 at the early phase of infection including circulation of immature neutrophils, depletion of nonconventional monocytes, and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, activated follicular {T}-helper cells, and non-naive {G}ranzyme {B}(+){F}as{L}(+), {E}omes(high){TCF}-1(high), {PD}-1(+){CD}8(+) {T}c1 cells. {V}irus-induced lymphopenia worsened cancer-associated lymphocyte loss, and low lymphocyte counts correlated with chronic {SARS}-{C}o{V}-2 {RNA} shedding, {COVID}-19 severity, and a higher risk of cancer-related death in the first and second surge of the pandemic. {L}ymphocyte loss correlated with significant changes in metabolites from the polyamine and biliary salt pathways as well as increased blood {DNA} from {E}nterobacteriaceae and {M}icrococcaceae gut family members in long-term viral carriers. {W}e surmise that cancer therapies may exacerbate the paradoxical association between lymphopenia and {COVID}-19-related immunopathology, and that the prevention of {COVID}-19-induced lymphocyte loss may reduce cancer-associated death.},
  keywords = {{FRANCE} ; {CANADA}},
  booktitle = {},
  journal = {{C}ell {D}eath and {D}ifferentiation},
  volume = {28},
  numero = {12},
  pages = {3297--3315},
  ISSN = {1350-9047},
  year = {2021},
  DOI = {10.1038/s41418-021-00817-9},
  URL = {https://www.documentation.ird.fr/hor/fdi:010082273},
}